---
title: "Curis notifies press release availability on positive emavusertib update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293462544.md"
description: "Curis announced positive clinical data for emavusertib in the TakeAim Lymphoma study. In BTK inhibitor-naive primary CNS lymphoma patients, the overall response rate was 86% (100% in evaluable patients). For BTK inhibitor-experienced patients, the rate was 26% (33% in evaluable patients). Additionally, enrollment guidance for the TakeAim CLL study was updated, with 10 patients consented ahead of December 2026 data."
datetime: "2026-07-22T11:04:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293462544.md)
  - [en](https://longbridge.com/en/news/293462544.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293462544.md)
generator: "portal-rs"
---

# Curis notifies press release availability on positive emavusertib update

-   Curis released updated clinical data for emavusertib in its registrational TakeAim Lymphoma study in primary CNS lymphoma. \* BTK inhibitor-naive PCNSL showed 86% overall response rate across all patients as of July 1, 2026; 100% in evaluable patients. \* BTK inhibitor-experienced PCNSL showed 26% overall response rate across all patients; 33% in evaluable patients. \* TakeAim CLL enrollment guidance for December 2026 data increased to 5-10 patients; 10 patients consented. \* Webcast details posted at here Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607220700PR\_NEWS\_USPR\_\_\_\_\_NE09816) on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CRIS.US](https://longbridge.com/en/quote/CRIS.US.md)

## Related News & Research

- [CRIS: Emavusertib shows superior efficacy and safety in NHL, CLL, and AML, advancing in registrational trials](https://longbridge.com/en/news/293485845.md)
- [CRIS: Emavusertib shows strong response rates in PCNSL and advances in CLL, pending further funding](https://longbridge.com/en/news/293464781.md)
- [New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma | NTRA Stock News](https://longbridge.com/en/news/297636654.md)
- [Patient enrolment concludes in Senhwa’s Phase Ib trial of pidnarulex](https://longbridge.com/en/news/298029888.md)
- [TipRanks Analyst Salveen Richter Reiterates Buy on Braveheart Bio, Sets $48 12-Month Target on Strong HCM Opportunity for Lead Asset BHB-1893](https://longbridge.com/en/news/297471640.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**